The drug store operator reported earnings of $1.13 a share for the second quarter, beating the Capital IQ Consensus Estimate of $1.10 a share by 3 cents. Revenue grew 10.7% from the year-ago quarter to $34.6 billion. Analysts expected revenue of $33.47 billion for the quarter.
CVS raised its earnings forecast for the full-year 2014 to between $4.43 and $4.51, up from its previous guidance of $4.36 to $4.50 a share. Analysts expect earnings of $4.46 a share for the year.
TheStreet Ratings team rates CVS CAREMARK CORP as a Buy with a ratings score of A+. TheStreet Ratings Team has this to say about their recommendation:
"We rate CVS CAREMARK CORP (CVS) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins."